Non-Melanoma Skin Cancer Market to Gain Momentum Globally, States Black Swan Analysis in Its Research Report Available at MarketPublishers.com

05 Oct 2016 • by Natalie Aster

LONDON – Non-melanoma skin cancer (NMSC) is one of the most generally occurring cancer types, though not having a tendency to be reported via registries as patients’ prognosis is optimistic in the majority of cases. The market is projected to gain rapid momentum in the years to come, stimulated mainly by the increasing prevalence of the sisease resulting from such factors as increasing exposure to UV rays, depletion of ozone layer, and genetic mutations, among others. Common teatments for non-melanoma skin cancer include surgery, cryotherapy, laser therapy, creams, chemotherapy, radiotherapy, and PDT.

There are 2 key types of NMSC malignancies, namely basal cell carcinoma (BCC, or basalioma) and squamous cell carcinoma (SCC). The former is the most typical type of cancer, especially across the USA, and represents a heterogeneous group of tumours that can be superficially or deeply invasive and hence life threatening.

People with specific skin conditions, like psoriasis, actinic keratosis and xeroderma pigmentosum, may also be in danger of developing skin cancer.

In-demand report “Epiomic Epidemiology Series: Non-Melanoma Skin Cancer Forecast in 8 Major Markets 2016-2026” elaborated by Black Swan Analysis provides an up-close look at the present-day diagnosed prevalent population in 8 leading markets, namely the USA, Spain, Germany, Italy, the UK, Japan, France and Brazil, broken down by five-year age cohort and gender. In tandem with today’s prevalence, the study also gives an in-depth review of the risk factors, key symptoms, diagnosis and prognosis of the disease as well as particular variations by ethnicity and geography. The report identifies the patient populations in the worldwide NMSC marketplace, which is essential for targeting the development of pricing strategies and future products, and also launch plans. It covers the prevalence rate of the subdivided types of NMSC and also pinpoints patient segments that hold high potential. The study delivers trustworthy insights into clinical trials in study sizing and realistic patient recruitment for different countries. The research report gives a deep understanding of the impact from particular co-morbid conditions on the NMSC prevalent population. The study covers the sub-populations within the disease country-wise across the ten-year forecast snapshot. Additionally, the report casts light on the specific markets with the biggest number of NMSC patients.

More studies by our market research partner can be found at Black Swan Analysis page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com